The combination therapy with zoledronic acid and propranolol improves the trabecular microarchitecture and mechanical property in an rat model of postmenopausal osteoporosis

Journal of Osteoporosis

Volumn 2014, Issue , 2014, Pages

  Khajuria, Deepak Kumar ^a,b   Razdan, Rema ^a   Mahapatra, D Roy ^b  

^a AL AMEEN COLLEGE OF PHARMACY   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

PROPRANOLOL; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE STRENGTH; BONE STRUCTURE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; FEMUR SHAFT; LUMBAR SPINE; MONOTHERAPY; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; POSTMENOPAUSE OSTEOPOROSIS; RAT; SHAM PROCEDURE; SINGLE DRUG DOSE; TRABECULAR BONE; TREATMENT DURATION; WISTAR RAT;

EID: 84899583753     PISSN: 20908059     EISSN: 20420064     Source Type: Journal    
DOI: 10.1155/2014/586431     Document Type: Article

References (32)

1. Khajuria D. K., Razdan R., Mahapatra D. R., Drugs for the management of osteoporosis: a review. Revista Brasileira de Reumatologia 2011 51 4 365 382 2-s2.0-79960580658
2. Hohenhaus M. H., McGarry K. A., Col N. F., Hormone therapy for the prevention of bone loss in menopausal women with osteopenia: is it a viable option? Drugs 2007 67 16 2311 2321 2-s2.0-35948968822 (Pubitemid 350071044)
3. Black D. M., Delmas P. D., Eastell R., Reid I. R., Boonen S., Cauley J. A., Cosman F., Lakatos P., Ping C. L., Man Z., Mautalen C., Mesenbrink P., Hu H., Caminis J., Tong K., Rosario-Jansen T., Krasnow J., Hue T. F., Sellmeyer D., Eriksen E. F., Cummings S. R., Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New England Journal of Medicine 2007 356 18 1809 1822 2-s2.0-34247866550 10.1056/NEJMoa067312 (Pubitemid 46698462)
4. Coxon F. P., Helfrich M. H., Van't Hof R., Sebti S., Ralston S. H., Hamilton A., Rogers M. J., Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. Journal of Bone and Mineral Research 2000 15 8 1467 1476 2-s2.0-0033930168 (Pubitemid 30484516)
5. Nielsen O. S., Munro A. J., Tannock I. F., Bone metastases: pathophysiology and management policy. Journal of Clinical Oncology 1991 9 3 509 524 2-s2.0-0025969367
6. Benford H. L., McGowan N. W. A., Helfrich M. H., Nuttall M. E., Rogers M. J., Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001 28 5 465 473 2-s2.0-0035051719 10.1016/S8756-3282(01)00412-4 (Pubitemid 32409997)
7. Gasser J. A., Ingold P., Venturiere A., Shen V., Green J. R., Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. Journal of Bone and Mineral Research 2008 23 4 544 551 2-s2.0-41849119494 10.1359/jbmr.071207 (Pubitemid 351501895)
8. Khajuria D. K., Razdan R., Mahapatra D. R., Bhat M. R., Osteoprotective effect of propranolol in ovariectomized rats: a comparison with zoledronic acid and alfacalcidol. Journal of Orthopaedic Science 2013 18 5 832 842
9. Khajuria D. K., Disha C., Razdan R., Mahapatra D. R., Comparative evaluation of zoledronic acid, alfacalcidol, and propranolol in pharmacological correction of experimental osteoporosis. Latin American Journal of Pharmacy 2013 32 7 968 976
10. Khajuria D. K., Disha C., Razdan R., Mahapatra D. R., Vasireddi R., Prophylactic effects of propranolol versus standard therapy on a new model of disuse osteoporosis in rats. Scientia Pharmaceutica 2013 10.3797/scipharm.1310- 06
11. Papapetrou P. D., Bisphosphonate-associated adverse events. Hormones 2009 8 2 96 110 2-s2.0-69149089717
12. Brouwers J. E. M., van Rietbergen B., Bouxsein M. L., Influence of early and late zoledronic acid administration on vertebral structure and strength in ovariectomized rats. Calcified Tissue International 2008 83 3 186 191 2-s2.0-52649179885 10.1007/s00223-008-9160-3
13. Togari A., Arai M., Pharmacological topics of bone metabolism: the physiological function of the sympathetic nervous system in modulating bone resorption. Journal of Pharmacological Sciences 2008 106 4 542 546 2-s2.0-42349092162 10.1254/jphs.FM0070227 (Pubitemid 351556230)
14. Takeda S., Karsenty G., Molecular bases of the sympathetic regulation of bone mass. Bone 2008 42 5 837 840 2-s2.0-41949123246 10.1016/j.bone.2008.01.005
15. Hamrick M. W., Ferrari S. L., Leptin and the sympathetic connection of fat to bone. Osteoporosis International 2008 19 7 905 912 2-s2.0-44449087465 10.1007/s00198-007-0487-9 (Pubitemid 351758616)
16. Bonnet N., Benhamou C. L., Malaval L., Goncalves C., Vico L., Eder V., Pichon C., Courteix D., Low dose beta-blocker prevents ovariectomy-induced bone loss in rats without affecting heart functions. Journal of Cellular Physiology 2008 217 3 819 827 2-s2.0-54049122252 10.1002/jcp.21564
17. Sato T., Arai M., Goto S., Togari A., Effects of propranolol on bone metabolism in spontaneously hypertensive rats. Journal of Pharmacology and Experimental Therapeutics 2010 334 1 99 105 2-s2.0-77953792066 10.1124/jpet.110.167643
18. Lezón C. E., Pintos P. M., Olivera M. I., Bozzini C., Boyer P. M., Effect of different propranolol doses on skeletal structural and mechanic efficiency in an animal model of growth retardation. Endocrinologia y Nutricion 2012 59 1 9 20 2-s2.0-84856224410 10.1016/j.endonu.2011.09.006
19. Bonnet N., Gadois C., McCloskey E., Lemineur G., Lespessailles E., Courteix D., Benhamou C. L., Protective effect of β blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone 2007 40 5 1209 1216 2-s2.0-34147163299 10.1016/j.bone.2007.01.006 (Pubitemid 46553796)
20. de Vries F., Souverein P. C., Cooper C., Leufkens H. G. M., van Staa T. P., Use of β -blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands. Calcified Tissue International 2007 80 2 69 75 2-s2.0-33847100425 10.1007/s00223-006-0213-1 (Pubitemid 46294972)
21. Meisinger C., Heier M., Lang O., Döring A., β -blocker use and risk of fractures in men and women from the general population: the MONICA/KORA Augsburg cohort study. Osteoporosis International 2007 18 9 1189 1195 2-s2.0-34548120660 10.1007/s00198-007-0354-8 (Pubitemid 47300270)
22. Ringe J. D., Combination therapy in osteoporosis: basic therapy plus specific osteoporosis drug. Medizinische Monatsschrift fur Pharmazeuten 2009 32 4 137 140 2-s2.0-65249105499
23. 2 on bone mineral density and strength in ovariectomized mice. Journal of Bone and Mineral Metabolism 2010 28 4 403 409 2-s2.0-77956456573 10.1007/s00774-009-0148-5
24. Rodrigues W. F., Madeira M. F. M., da Silva T. A., Clemente-Napimoga J. T., Miguel C. B., Dias-Da-Silva V. J., Barbosa-Neto O., Lopes A. H., Napimoga M. H., Low dose of propranolol down-modulates bone resorption by inhibiting inflammation and osteoclast differentiation. British Journal of Pharmacology 2012 165 7 2140 2151 2-s2.0-84858213536 10.1111/j.1476-5381.2011.01686.x
25. Huang H. H., Brennan T. C., Muir M. M., Mason R. S., Functional α 1- and β 2-adrenergic receptors in human osteoblasts. Journal of Cellular Physiology 2009 220 1 267 275 2-s2.0-65549105822 10.1002/jcp.21761
26. Khajuria D. K., Razdan R., Mahapatra D. R., Description of a new method of ovariectomy in female rats. Revista Brasileira de Reumatologia 2012 52 3 466 470
27. Cheng Z., Yao W., Zimmermann E. A., Busse C., Ritchie R. O., Lane N. E., Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats. Journal of Bone and Mineral Research 2009 24 2 209 220 2-s2.0-58649123545 10.1359/jbmr.81005
28. Leppänen O. V., Sievänen H., Järvinen T. L., Biomechanical testing in experimental bone interventions-may the power be with you. Journal of Biomechanics 2008 4 8 1623 1631
29. Bergner R., Diel I. J., Henrich D., Hoffmann M., Uppenkamp M., Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 2006 29 11 534 540 2-s2.0-33750293909 10.1159/000096056 (Pubitemid 44631677)
30. Black D. M., Delmas P. D., Eastell R., Reid I. R., Boonen S., Cauley J. A., Cosman F., Lakatos P., Ping C. L., Man Z., Mautalen C., Mesenbrink P., Hu H., Caminis J., Tong K., Rosario-Jansen T., Krasnow J., Hue T. F., Sellmeyer D., Eriksen E. F., Cummings S. R., Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New England Journal of Medicine 2007 356 18 1809 1822 2-s2.0-34247866550 10.1056/NEJMoa067312 (Pubitemid 46698462)
31. Lévy S., Pharmacologic management of atrial fibrillation: current therapeutic strategies. American Heart Journal 2001 141 2 S15 S21 2-s2.0-0035151065 (Pubitemid 32128714)
32. Ray B. I., Atrial fibrillation: present treatment protocols by drugs and interventions. Journal of the Indian Academy of Clinical Medicine 2003 4 3 213 227